clobenpropit has been researched along with Parkinson Disease in 2 studies
clobenpropit: histamine H3 receptor antagonist
clobenpropit : An imidothiocarbamic ester that consists of isothiourea bearing S-3-(imidazol-4-yl)propyl and N-4-chlorobenzyl substituents. An extremely potent histamine H3 antagonist/inverse agonist (pA2 = 9.93). Also displays partial agonist activity at H4 receptors; induces eosinophil shape change with an EC50 of 3 nM.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, A | 2 |
| Muresanu, DF | 2 |
| Patnaik, R | 1 |
| Menon, PK | 1 |
| Tian, ZR | 2 |
| Sahib, S | 1 |
| Castellani, RJ | 1 |
| Nozari, A | 2 |
| Lafuente, JV | 2 |
| Buzoianu, AD | 2 |
| Skaper, SD | 1 |
| Bryukhovetskiy, I | 1 |
| Manzhulo, I | 1 |
| Wiklund, L | 2 |
| Sharma, HS | 2 |
| Feng, L | 1 |
| Huang, H | 1 |
| Chen, L | 1 |
2 reviews available for clobenpropit and Parkinson Disease
| Article | Year |
|---|---|
Histamine H3 and H4 receptors modulate Parkinson's disease induced brain pathology. Neuroprotective effects of nanowired BF-2649 and clobenpropit with anti-histamine-antibody therapy.
Topics: Corpus Striatum; Histamine; Humans; Imidazoles; Neuroprotective Agents; Parkinson Disease; Receptors | 2021 |
Nanodelivery of Histamine H3/H4 Receptor Modulators BF-2649 and Clobenpropit with Antibodies to Amyloid Beta Peptide in Combination with Alpha Synuclein Reduces Brain Pathology in Parkinson's Disease.
Topics: alpha-Synuclein; Amyloid beta-Peptides; Antibodies, Monoclonal; Brain; Drug Inverse Agonism; Histami | 2023 |